Reported 20,926 shares, down 800 (3.7%) from the prior quarter.
Reported value -42.3%; share count -3.7% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2022-09-30 | 136000 |
| 2022-12-31 | 42117 |
| 2023-03-31 | 46174 |
| 2023-06-30 | 33244 |
| 2023-09-30 | 3229 |
| 2023-12-31 | 5737 |
| 2024-03-31 | 12269 |
| 2024-06-30 | 7083 |
| 2024-09-30 | 3189 |
| 2024-12-31 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q4 2024 | Reduced | 0 | -13,846 (-100.0%) | 0 | $0 | 2025-02-14 | |
| Q3 2024 | Reduced | 13,846 | -7,080 (-33.8%) | < 0.01% | $3,189 | 2024-10-11 | |
| Q2 2024 | Reduced | 20,926 | -800 (-3.7%) | < 0.01% | $7,083 | 2024-08-15 | |
| Q1 2024 | Added | 21,726 | +710 (3.4%) | < 0.01% | $12,269 | 2024-05-13 | |
| Q4 2023 | Added | 21,016 | +4,878 (30.2%) | < 0.01% | $5,737 | 2024-02-14 | |
| Q3 2023 | Unchanged | 16,138 | 0 (0.0%) | < 0.01% | $3,229 | 2023-11-16 | |
| Q2 2023 | Added | 16,138 | +2,146 (15.3%) | < 0.01% | $33,244 | 2023-07-21 | |
| Q1 2023 | Reduced | 13,992 | -11,689 (-45.5%) | < 0.01% | $46,174 | 2023-05-15 | |
| Q4 2022 | Reduced | 25,681 | -5,000 (-16.3%) | < 0.01% | $42,117 | 2023-02-10 | |
| Q3 2022 | New | 30,681 | +30,681 (0.0%) | < 0.01% | $136,000 | 2022-11-03 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
55 managers reported BRAINSTORM CELL THERAPEUTICS I for Q2 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL LLC | New | 7,917,653 | +7,917,653 | 0.03% | $2,680,126 | 1 qtr |
| VANGUARD GROUP INC | Added | 1,510,640 | +109,647 | < 0.01% | $511,352 | 38 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Added | 484,285 | +127,244 | < 0.01% | $163,986 | 39 qtrs |
| BlackRock Inc | Reduced | 386,414 | -102,899 | < 0.01% | $130,801 | 30 qtrs |
| LIBERTY WEALTH MANAGEMENT LLC | Unchanged | 340,150 | 0 | 0.02% | $115,000 | 6 qtrs |
| Weaver Consulting Group | Added | 234,356 | +35,000 | 0.03% | $79,330 | 14 qtrs |
| ABNER HERRMAN & BROCK LLC | Unchanged | 145,500 | 0 | < 0.01% | $49,000 | 18 qtrs |
| STATE STREET CORPORATION | Added | 117,260 | +21,200 | < 0.01% | $39,693 | 17 qtrs |
| NORTHERN TRUST CORPORATION | Added | 112,358 | +57,570 | < 0.01% | $38,033 | 38 qtrs |
| RAYMOND JAMES & ASSOCIATES | Reduced | 111,285 | -2,500 | < 0.01% | $37,670 | 20 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2024
- Filed
- August 15, 2024
- Filing type
- 13F-HR
- Position type
- COM NEW
Voting authority reported
- Sole
- 0
- Shared
- 0
- None
- 20,926
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.